Cartesian Therapeutics Inc (RNAC) Stock Price, Quote & News

Company Profile

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 348 8698

Website: www.cartesiantherapeutics.com

Address:

7495 New Horizon Way, Frederick, United States

Th3M4skedSt0nker Apr. 20 at 3:24 PM

$RNAC investors, if you wanna do something good with your money and help Myasthenia Gravis patients while making reasonable money you better forget this POS and check the latest remarkable $KYTX data released today with a 100% efficacy and a superior safety profile. Good luck Ladies and Gentlemen 💲💲💲

0 · Reply

thedavidsonny Apr. 20 at 2:04 PM

$RNAC $GREE $EFOI $WLDS 🔥 🔥 🔥 🔥 🔥 🔥

0 · Reply

STACKD0E Apr. 20 at 1:48 PM

$RNAC $GREE $EFOI $WLDS

0 · Reply

SGL_FGHI Apr. 17 at 2:51 PM

$RNAC Interesting to see Fidelity has top institutional and mutual fund holder interests here: FMR, LLC; Fidelity Select Portfolios-Select Biotechnology Portfolio; Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund; Fidelity Salem Street Trust-Fidelity Small Cap Index Fund; and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund.

1 · Reply

doDD22 Apr. 17 at 1:11 PM

$RNAC 10 shares pump = setup lol

0 · Reply

doDD22 Apr. 16 at 9:14 AM

$RNAC 1) no point in talking about SELB CVRs until they are paid March/September. That chapter is completely done. Now you read SOBI NASP notes. Based on projections, it seems like a favorable dividend payment every year. 2) RNAC is going to continue to be weak until Phase 3 data 2027 ish. The May ER will probably get slammed as cash burn will continue and there are no meaningful partnerships. Phase 2 looked promising with a small group. Phase 3 is the test. If they pass, this will do well and the platform will be valid. If not, bye bye money. If you own this, I would just ignore it until 2027. Dilution may also happen if cash burn accelerates due to Phase 3 trials, likely. Overall, everything rides on Phase 3. However, that may take more than 18 months.

1 · Reply

BowernTrumpl Apr. 14 at 8:42 AM

$RNAC any news an the CVR money?.... still have 27k in my account worth nothing

1 · Reply

YOLOartist Apr. 8 at 1:41 AM

$RNAC Honestly, just completely dissolve already so I can move on with my life.

1 · Reply

EmbryonicJourney Apr. 4 at 7:31 PM

$RNAC Springer not bought in over a year - we could definitely do with a some upward momentum from here. He always tends to have that effect

0 · Reply

focafoca99 Mar. 31 at 1:28 AM

$RNAC's update is a clean board change: Murat Kalayoglu is stepping off the board at month-end, and the filing says it is not over any disagreement.

1 · Reply

Cartesian Therapeutics Announces New Employment Inducement Grants

Jan 9, 2026, 8:04 AM EST - 3 months ago

Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook

Dec 18, 2025, 4:05 PM EST - 4 months ago

Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors

Oct 3, 2025, 7:05 AM EDT - 7 months ago

Cartesian Therapeutics Announces New Employment Inducement Grant

Aug 28, 2025, 7:00 AM EDT - 8 months ago

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

May 30, 2025, 7:00 AM EDT - 11 months ago

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

May 8, 2025, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 8, 2025, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Jan 27, 2025, 7:00 AM EST - 1 year ago

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis

Dec 3, 2024, 6:00 AM EST - 1 year ago

Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

Nov 21, 2024, 7:00 AM EST - 1 year ago

Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15

Jul 2, 2024, 4:05 PM EDT - 1 year ago

Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik

Jul 2, 2024, 6:40 AM EDT - 1 year ago

Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage study

Jul 2, 2024, 6:31 AM EDT - 1 year ago

Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing

Jul 2, 2024, 6:31 AM EDT - 1 year ago

Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus

Jul 2, 2024, 6:30 AM EDT - 1 year ago

Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

May 22, 2024, 7:00 AM EDT - 2 years ago

Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis

May 13, 2024, 4:30 PM EDT - 2 years ago

Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 8, 2024, 7:00 AM EDT - 2 years ago

Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 22, 2024, 4:30 PM EDT - 2 years ago

Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting

Apr 4, 2024, 7:30 AM EDT - 2 years ago

Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split

Mar 7, 2024, 7:00 AM EST - 2 years ago

Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Mar 5, 2024, 7:00 AM EST - 2 years ago

Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland

Th3M4skedSt0nker Apr. 20 at 3:24 PM

0 · Reply

thedavidsonny Apr. 20 at 2:04 PM

$RNAC $GREE $EFOI $WLDS 🔥 🔥 🔥 🔥 🔥 🔥

0 · Reply

STACKD0E Apr. 20 at 1:48 PM

$RNAC $GREE $EFOI $WLDS

0 · Reply

SGL_FGHI Apr. 17 at 2:51 PM

1 · Reply

doDD22 Apr. 17 at 1:11 PM

$RNAC 10 shares pump = setup lol

0 · Reply

doDD22 Apr. 16 at 9:14 AM

1 · Reply

BowernTrumpl Apr. 14 at 8:42 AM

$RNAC any news an the CVR money?.... still have 27k in my account worth nothing

1 · Reply

YOLOartist Apr. 8 at 1:41 AM

$RNAC Honestly, just completely dissolve already so I can move on with my life.

1 · Reply

EmbryonicJourney Apr. 4 at 7:31 PM

$RNAC Springer not bought in over a year - we could definitely do with a some upward momentum from here. He always tends to have that effect

0 · Reply

focafoca99 Mar. 31 at 1:28 AM

$RNAC's update is a clean board change: Murat Kalayoglu is stepping off the board at month-end, and the filing says it is not over any disagreement.

1 · Reply

ThomasTrainTrader Mar. 27 at 5:01 PM

$RNAC maybe everyone can make their money back if we bet YES on Kalshi that Casten Brunn will go to prison

0 · Reply

doDD22 Mar. 27 at 3:32 PM

$RNAC I want $4

0 · Reply

ThomasTrainTrader Mar. 27 at 12:36 AM

$RNAC Carsten Brunn is still making $6 million in salary right?

1 · Reply

InjureReserve Mar. 25 at 11:45 AM

$RNAC from IR: Currently, there are ~178 million CVRs that currently exist today. In regards to the $30M milestone payment, all deductions on this CVR distribution were made in accordance with the express terms of the CVR Agreement, which is publicly available on the SEC’s website. As required by the CVR Agreement, Cartesian has provided the CVR Agent, Equiniti, with an accounting of the payment and related deductions. Please contact Equiniti (contact information below), who is acting as your agent, with any further questions you may have relating to the CVR terms and related payments. We also cannot comment on any future lease liabilities that remain. Equiniti Trust Company, LLC 6201 15th Avenue Brooklyn, NY 11219 800-937-5449

0 · Reply

doDD22 Mar. 19 at 1:12 PM

$RNAC Felt something fishy with that pump Still watching and waiting

1 · Reply

azv134 Mar. 19 at 12:31 PM

$RNAC buying back today. This is ridiculously cheap

1 · Reply

Meydamax315 Mar. 19 at 9:01 AM

$RNAC what a disaster. I lost so much money on this dog shit.

0 · Reply

StocktwitsEarnings Mar. 19 at 9:00 AM

$RNAC Q4 '25 Earnings Results & Recap Cartesian Therapeutics, Inc. expects its existing cash, cash equivalents, and restricted cash of $126.9M as of December 31, 2025, to fund operating expenses and capital expenditures for at least the next 12 months.

0 · Reply

kimgysen Mar. 18 at 7:00 PM

$RNAC When you think it can't get worse lol

0 · Reply

LoveRetailFroth Mar. 16 at 3:47 PM

$DTIL My Bio additions this yr $RCKT $RNAC $PALI $SMMT

0 · Reply

kimgysen Mar. 13 at 3:56 PM

$RNAC

0 · Reply

patience_needed Mar. 11 at 4:24 PM

$RNAC Hey all. So what’s the latest on CVRs? Should we expect a payout of any sorts around the end of the month?? TIA

1 · Reply

Market Cap	183.97M
Revenue (ttm)	2.80M
Net Income (ttm)	-130.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,653.57%
Debt to Equity Ratio	0.00

Volume	127,200
Avg Vol	213,570
Day's Range	N/A - N/A
Shares Out	26.51M
Stochastic %K	77%
Beta	0.47
Analysts	Strong Sell
Price Target	$35.57